Related Experiment Video
Updated: Jul 30, 2025
Anticancer Efficacy of Photodynamic Therapy with Lung Cancer-Targeted Nanoparticles
Published on: December 1, 2016
Erlotinib-Loaded Dendrimer Nanocomposites as a Targeted Lung Cancer Chemotherapy
Wafa K Fatani1, Fadilah S Aleanizy1, Fulwah Y Alqahtani1
1Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.
Abstract:
Lung cancer is the main cause of cancer-related mortality globally. Erlotinib is a tyrosine kinase inhibitor, affecting both cancerous cell proliferation and survival. The emergence of oncological nanotechnology has provided a novel drug delivery system for erlotinib. The aims of this current investigation were to formulate two different polyamidoamine (PAMAM) dendrimer generations-generation 4 (G4) and generation 5 (G5) PAMAM dendrimer-to study the impact of two different PAMAM dendrimer formulations on entrapment by drug loading and encapsulation efficiency tests; to assess various characterizations, including particle size distribution, polydispersity index, and zeta potential; and to evaluate in vitro drug release along with assessing in situ human lung adenocarcinoma cell culture. The results showed that the average particle size of G4 and G5 nanocomposites were 200 nm and 224.8 nm, with polydispersity index values of 0.05 and 0.300, zeta potential values of 11.54 and 4.26 mV of G4 and G5 PAMAM dendrimer, respectively. Comparative in situ study showed that cationic G4 erlotinib-loaded dendrimer was more selective and had higher antiproliferation activity against A549 lung cells compared to neutral G5 erlotinib-loaded dendrimers and erlotinib alone. These conclusions highlight the potential effect of cationic G4 dendrimer as a targeting-sustained-release carrier for erlotinib.
Insights
Cationic generation 4 polyamidoamine (PAMAM) dendrimers show enhanced anti-lung cancer activity. These dendrimers effectively deliver erlotinib, improving drug delivery and targeting for cancer treatment.
Area of Science:
- Nanomedicine
- Oncology
- Materials Science
Background:
- Lung cancer remains a leading global cause of cancer mortality.
- Erlotinib, a tyrosine kinase inhibitor, targets cancer cell proliferation and survival.
- Nanotechnology offers novel drug delivery systems for cancer therapeutics like erlotinib.
Purpose of the Study:
- To formulate and characterize two generations (G4 and G5) of polyamidoamine (PAMAM) dendrimers for erlotinib delivery.
- To evaluate drug loading, encapsulation efficiency, particle characteristics, and in vitro release.
- To assess the in situ antiproliferative efficacy against human lung adenocarcinoma cells.
Main Methods:
- Formulation of G4 and G5 PAMAM dendrimers loaded with erlotinib.
- Characterization of nanocomposites: particle size, polydispersity index, and zeta potential.
- In vitro drug release studies and in situ antiproliferation assays using A549 lung cells.
Main Results:
- G4 and G5 PAMAM dendrimer nanocomposites exhibited average particle sizes of 200 nm and 224.8 nm, respectively.
- Polydispersity index values were 0.05 for G4 and 0.300 for G5.
- Zeta potential values were 11.54 mV for G4 and 4.26 mV for G5, indicating cationic and neutral properties.
Conclusions:
- Cationic G4 erlotinib-loaded dendrimers demonstrated superior selectivity and antiproliferation activity against A549 lung cells compared to G5 dendrimers and erlotinib alone.
- The study highlights the potential of cationic G4 dendrimers as effective carriers for targeted, sustained release of erlotinib.
- PAMAM dendrimer generation significantly influences the characteristics and efficacy of erlotinib drug delivery systems.
More Related Videos
07:53Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
Published on: April 26, 2016
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
